Reblozyl 75 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FQV4K
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $23,106
Award facts
- Contract value 100% obligated
- $23,106.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $23,106.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp (parent company: Cencora, Inc.) on January 28, 2026, for the supply of Reblozyl 75 mg vials. The contract is non-competitive and utilizes an Indefinite Delivery Contract vehicle with the DLA Troop Support Medical (SPE2DX), valued at up to $999,999,999.00 and extending through December 2026. This delivery order represents a task order placed against the larger pharmaceutical prime vendor contract that enables AmerisourceBergen to supply a comprehensive range of medications and medical supplies to support military healthcare systems globally. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of February 19, 2026.
Reblozyl (luspatercept-aamt) is a specialized pharmaceutical used primarily in the treatment of anemia associated with myelodysplastic syndromes and beta-thalassemia. As a critical healthcare solutions provider to federal agencies, AmerisourceBergen maintains significant contract capacity to deliver specialty medications and medical commodities across multiple therapeutic domains to Defense Health Agency facilities, the U.S. Coast Guard, and other government healthcare systems. This delivery order reflects the ongoing demand for specialty pharmaceutical products within military medical supply chains and the company's established capability to meet federal procurement requirements through its prime vendor relationship with DLA.
Quick answers
Who was awarded contract SPE2DR26FQV4K?
SPE2DR26FQV4K was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FQV4K worth?
The government has obligated $23,106 on SPE2DR26FQV4K.
Is contract SPE2DR26FQV4K an order under another contract?
Yes. SPE2DR26FQV4K is a delivery order under SPE2DR25D1022, an indefinite delivery contract.
Was contract SPE2DR26FQV4K competed?
The extent of competition for SPE2DR26FQV4K was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award